

Plx-4032

Chemical Properties


CAS No. : 1029872-54-5

Formula: C₂₃H₁₈ClF₂N₃O₃S

Molecular Weight: 489.92

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	Plx-4032 (Vemurafenib) is a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.
Targets(IC50)	Raf
In vivo	PLX-4032 and its related analogs are highly potent inhibitors of B-Raf activity, with 3-fold selectivity for the V600E mutation over the wild-type kinase. In preclinical models, PLX-4032 and its analogs inhibited the growth of BRAFV600E-positive melanoma cell lines both in vitro and in vivo[1].

Solubility Information

Solubility	Ethanol: 1.41 mg/mL (2.88 mM),Sonication is recommended. DMSO: 72.86 mg/mL (148.72 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 7.29 mg/mL (14.88 mM),Solution. 10% DMSO+90% Saline: < 7.29 mg/mL (14.88 mM),Lower concentrations may be soluble, but exact solubility limit is unknown. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.0411 mL	10.2057 mL	20.4115 mL
5 mM	0.4082 mL	2.0411 mL	4.0823 mL
10 mM	0.2041 mL	1.0206 mL	2.0411 mL
50 mM	0.0408 mL	0.2041 mL	0.4082 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Smalley K S M . PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.[J]. Current Opinion in Investigational Drugs, 2010, 11(6):699-706.
- Chapman, Paul, B, et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation.[J]. New England Journal of Medicine, 2011.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481